Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2012
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.
- Teriflunomide for multiple sclerosis.The Cochrane database of systematic reviews · 2016Pooled it
- Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Trial
- Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.Chinese medical journal · 2018Trial
- Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.Neurology · 2016Trial
- Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.Journal of neurology · 2014Trial
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.Neurology · 2013Trial
- Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer.Oncogenesis · 2026Article
- Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia.Annals of African medicine · 2025Article
- Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.Neurology and therapy · 2023Article
- A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis.Neurology international · 2021Article
- The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.CNS drugs · 2021Review
- Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.Frontiers in immunology · 2021Article
- Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies.Journal of central nervous system disease · 2021Article
- Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.Neurology research international · 2021Article
- Progress in the Application of Drugs for the Treatment of Multiple Sclerosis.Frontiers in pharmacology · 2021Review
- Review
- Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.Neurology · 2019Article
- Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase.Molecules (Basel, Switzerland) · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTeriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective in reducing magnetic resonance imaging (MRI) lesions in 179 RMS patients in a phase 2 36-week, placebo-controlled study.
methodsA total of 147 patients who completed the core study entered an open-label extension. Teriflunomide patients continued their assigned dose, and placebo patients were re-allocated to teriflunomide, 7 mg/day or 14 mg/day. An interim analysis was performed at a cut-off on January 8 2010.
resultsThe mean and median duration of study treatment, including both the core and extension phase, from baseline to the interim cut-off, was 5.6 years (standard deviation: 2.7 years) and 7.1 years (range: 0.05-8.5 years), respectively. Of 147 patients, 62 (42.2%) discontinued (19% due to treatment-emergent adverse events (TEAEs)). The most common TEAEs were mild infections, fatigue, sensory disturbances and diarrhoea. No serious opportunistic infections occurred, with no discontinuations due to infection. Asymptomatic alanine aminotransferase increases (≤3× upper limit of normal (ULN)) were common (7 mg, 64.2%; 14 mg, 62.1%); increases >3×ULN were similar across groups (7 mg, 12.3%; 14 mg, 12.1%). Mild decreases in neutrophil counts occurred; none led to discontinuation. The incidence of malignancies was comparable to that of the general population, and cases were not reminiscent of those observed in immunocompromised patients. Annualised relapse rates remained low, minimal disability progression was observed, with a dose-dependent benefit with teriflunomide 14 mg for several MRI parameters.
conclusionTeriflunomide had a favourable safety profile for up to 8.5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.